TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma

Published:2020-06-16 Issue:2 Volume:22 Page:1187-1194
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Rep

Author:

Zhang Wei¹,Zheng Xiaoxiao²,Xie Shangzhi²,Zhang Shufen²,Mao Jiayan²,Cai Ying²,Lu Xuemei²,Chen Wei²,Ni Haibin³,Xie Liping¹

Affiliation:

1. Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China

2. Department of Medical Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China

3. Department of General Surgery, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML‐05 trial;Pediatric Blood & Cancer;2024-07-02

2. Atractylenolide I Enhances Cisplatin Sensitivity in Renal Cell Carcinoma through Activation of FOXO1/ATG5 Pathway-Regulated Autophagy Hyperactivation;J BIOL REG HOMEOS AG;2023

3. Cisplatin Polylactic Acid Nanoparticles Combined with miR-181a Alleviates the Growth, Migration and Apoptosis of PG Cells in Lung Cancer Rats;Journal of Biomedical Nanotechnology;2023-06-01

4. Expression analysis of hsa_circ_0020397, hsa_circ_0005986, hsa_circ_0003028, and hsa_circ_0006990 in renal cell carcinoma;Experimental and Molecular Pathology;2023-02

5. Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML;Leukemia;2022-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3